Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.54 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | TPH1 | P17752 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2030773 | 1.00 | DPP4 (0.54) | DPP4DPP7ANPEPENPEPMME | |
| SCHEMBL288344 | 1.00 | DPP4 (0.54) | DPP4DPP7ANPEPENPEPMME | |
| SCHEMBL18683352 | 0.84 | DPP4 (0.52) | DPP4DPP7ANPEPENPEPDPP8 | |
| SCHEMBL25229867 | 0.83 | SLC7A5 (0.61) | ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL288276 | 0.83 | SLC7A5 (0.61) | ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL28064695 | 0.83 | ANPEP (0.51) | DPP4ANPEPENPEPMMP2CPA1 | |
| SCHEMBL288929 | 0.83 | ANPEP (0.51) | DPP4ANPEPENPEPMMP2CPA1 | |
| SCHEMBL28064621 | 0.83 | ANPEP (0.51) | DPP4ANPEPENPEPMMP2CPA1 | |
| SCHEMBL28064620 | 0.83 | ANPEP (0.51) | DPP4ANPEPENPEPMMP2CPA1 | |
| SCHEMBL27999577 | 0.83 | ANPEP (0.51) | DPP4ANPEPENPEPMMP2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12214043-B2 | Therapeutic nanomaterials | UNIVERSITY OF CONNECTICUT | 2025-02-04 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| EP-2027085-A1 | PROSTAGLANDIN EP4 AGONISTS | Allergan, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007115001-A1 | PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2007-10-04 | — | — | US | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | DPP4 1357/4885DPP7 865/4885ANPEP 205/4885 |
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | DPP4 361/4885DPP7 1120/4885ANPEP 431/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | DPP4 1217/4885DPP7 481/4885ANPEP 50/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | DPP4 1271/4885DPP7 1768/4885ANPEP 2209/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | DPP4 1374/4885DPP7 453/4885ANPEP 112/4885 |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | DPP4 361/4885DPP7 1120/4885ANPEP 431/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | DPP4 2835/4885DPP7 1615/4885ANPEP 76/4885 |
| US-12214043-B2 | Therapeutic nanomaterials | TIE1, TEKT1, POLRMT | DPP4 1357/4885DPP7 865/4885ANPEP 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.